Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Insuman er større end risiciene til behandling af sukkersyge (diabetes mellitus).
The Committee for Medicinal Products for Human Use (CHMP) decided that Insuman’ s benefits are greater than its risks for the treatment of diabetes mellitus.